USFDA issues 6 observations for Cipla Goa plant
Mumbai: Pharma major, Cipla has announced that the company has received six observations from the US Food and Drug Administration (USFDA) following the inspection conducted in August 2022 at its Goa plant.
The company said the Goa plant recently underwent a United States Food and Drug Administration (USFDA) inspection from August 16 to 26, 2022.
Earlier, the USFDA had inspected the company's Goa manufacturing facility in September 2019. A warning letter for the same was received by the company in February 2020.
Company further informed that on conclusion of the inspection, the company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity observations.
"The company will work closely with the US FDA and is committed to address these within the stipulated time, Company said in a filing with BSE.
Read also: Cipla EU to acquire additional 19.16 percent stake in Cipla Maroc
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Read also: Cipla gets CDSCO panel nod to study Rizatriptan Benzoate Orally Disintegrating Tablet
